Company & Sponsor Intelligence
University of California, Los Angeles
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed6
Countries1
Therapeutic footprint
anxietydepressionunclassified
Indexed studies
NCT06874790RCT for Latina Mental Health Using Web-Based Apps
anxiety · United StatesNA
anxiety · United StatesNA
NCT02317250Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
alzheimers · PHASE3
alzheimers · PHASE3
NCT01608295Vilazodone for Treatment of Geriatric Depression
anxiety · United StatesPHASE4
anxiety · United StatesPHASE4
NCT00956514Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder
depression · United StatesPHASE4
depression · United StatesPHASE4
NCT04851691An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
unclassified · United StatesNA
unclassified · United StatesNA
NCT03369418Effectiveness of CES on Emotional and Cellular Wellbeing
unclassified · United StatesNA
unclassified · United StatesNA
NCT03717922Low Intensity Focused Ultrasound for Learning and Memory and Emotion Regulation
unclassified · United StatesNA
unclassified · United StatesNA
NCT00759122Electroencephalography (EEG) Biomarkers of Response in Depression
depression · United StatesPHASE4
depression · United StatesPHASE4
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →